Mortality following bone metastasis and skeletal-related events among men with prostate cancer: A population-based analysis of US Medicare beneficiaries, 1999-2006

Prostate Cancer and Prostatic Diseases

Volumn 14, Issue 2, 2011, Pages 177-183

  Sathiakumar, N ^a   Delzell, E ^a   Morrisey, M A ^a   Falkson, C ^b   Yong, M ^c   Chia, V ^c   Blackburn, J ^a   Arora, T ^a   Kilgore, M L ^a  

^a UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^b UNIVERSITY OF ALABAMA SCHOOL OF MEDICINE   (United States)

^c AMGEN INC   (United States)

Author keywords

bone metastasis; mortality; prostate cancer bone involvement; skeletal related events

Indexed keywords

AGED; ARTICLE; BONE DISEASE; BONE METASTASIS; CANCER MORTALITY; CONTROLLED STUDY; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICARE; POPULATION RESEARCH; PRIORITY JOURNAL; PROGNOSIS; PROSTATE CANCER; RISK ASSESSMENT; RISK FACTOR; SKELETAL RELATED EVENT; UNITED STATES;

AGED; AGED, 80 AND OVER; BONE NEOPLASMS; COMORBIDITY; DATABASES, FACTUAL; FOLLOW-UP STUDIES; HUMANS; MALE; MEDICARE; PROPORTIONAL HAZARDS MODELS; PROSTATIC NEOPLASMS; REGISTRIES; UNITED STATES;

EID: 79956083610     PISSN: 13657852     EISSN: 14765608     Source Type: Journal    
DOI: 10.1038/pcan.2011.7     Document Type: Article

References (42)

1. Altekruse SF, Kosary CL, Krapcho M, Neyman N, Aminou R, Waldron W et al. (eds) SEER Cancer Statistics Review, 1975-2007 http://seer.cancer.gov/csr/1975- 2007/. based on November 2009 SEER data submission, posted to the SEER web site, 2010
2. Carlin BI, Andriole GL. The natural history, skeletal complications, and management of bone metastases in patients with prostate carcinoma. Cancer 2000; 88: 2989-2994 (Pubitemid 30413181)
3. Bridwell KH. Treatment of metastatic prostate cancer of the spine. Urol Clin North Am 1991; 18: 153-159
4. Keller ET, Zhang J, Cooper CR, Smith PC, McCauley LK, Pienta KJ et al. Prostate carcinoma skeletal metastases: cross-talk between tumor and bone. Cancer Metastasis Rev 2001; 20: 333-349 (Pubitemid 34595275)
5. Weinfurt KP, Li Y, Castel LD, Saad F, Timbie JW, Glendenning GA et al. The significance of skeletal-related events for the health-related quality of life of patients with metastatic prostate cancer. Ann Oncol 2005; 16: 579-584 (Pubitemid 40613323)
6. Ryan CJ, Elkin EP, Cowan J, Carroll PR. Initial treatment patterns and outcome of contemporary prostate cancer patients with bone metastases at initial presentation: data from CaPSURE. Cancer 2007; 110: 81-86 (Pubitemid 46986421)
7. Cooperberg MR, Broering JM, Carroll PR. Risk assessment for prostate cancer metastasis and mortality at the time of diagnosis. J Natl Cancer Inst 2009; 101: 878-887
8. Conti G, La Torre G, Cicalese V, Micheletti G, Ludovico MG, Vestita GD et al. Prostate cancer metastases to bone: observational study for the evaluation of clinical presentation, course and treatment patterns. Presentation of the METAURO protocol and of patient baseline features. Arch Ital Urol Androl 2008; 80: 59-64 (Pubitemid 351951362)
9. Norgaard M, Jensen AO, Jacobsen JB, Cetin K, Fryzek J, Sorensen HT. Skeletal related events, bone metastasis and survival of prostate cancer: A population based cohort study in Denmark (1999-2007). J Urol 2010; 184: 162-167
10. Potosky AL, Riley GF, Lubitz JD, Mentnech RM, Kessler LG. Potential for cancer related health services research using a linked Medicare-tumor registry database. Med Care 1993; 31: 732-748
11. Warren JL, Klabunde CN, Schrag D, Bach PB, Riley GF. Overview of the SEER-medicare data: content, research applications, and generalizability to the United States elderly population. Med Care 2002; 40: IV-3-18
12. Gornick ME, Warren JL, Eggers PW, Lubitz JD, De Lew N, Davis MH et al. Thirty years of medicare: impact on the covered population. Health Care Financ Rev 1996; 18: 179-237
13. Merrill RM. Partitioned prostate cancer prevalence estimates: an informative measure of the disease burden. J Epidemiol Community Health 2001; 55: 191-197 (Pubitemid 32163568)
14. Romano PS, Roos LL, Jollis JG. Adapting a clinical comorbidity index for use with ICD-9-CM administrative data: differing perspectives. J Clin Epidemiol 1993; 46: 1075-1079 discussion 81-90
15. Quan H, Sundararajan V, Halfon P, Fong A, Burnand B, Luthi JC et al. Coding algorithms for defining comorbidities in ICD-9-CM and ICD-10 administrative data. Med Care 2005; 43: 1130-1139 (Pubitemid 41587600)
16. Gooley TA, Leisenring W, Crowley J, Storer BE. Estimation of failure probabilities in the presence of competing risks: new representation of old estimators. Stat Med 1999; 18: 695-706 (Pubitemid 29126745)
17. Kalbfleish JD, Prentice RL. The Statistical Analysis of Failure Time Data. Wiley: New York, 1980
18. Cox DR. Regression models and life-tables (with discussion). J R Stat Soc Ser B 1972; 34: 187-220
19. Salonia A, Gallina A, Camerota TC, Picchio M, Freschi M, DaPozzo LF et al. Bone metastases are infrequent in patients with newly diagnosed prostate cancer: analysis of their clinical and pathologic features. Urology 2006; 68: 362-366 (Pubitemid 44175478)
20. Goodin S, Rao KV, DiPaola RS. State-of-the-art treatment of metastatic hormone-refractory prostate cancer. Oncologist 2002; 7: 360-370 (Pubitemid 34919960)
21. Clarke NW, Hart CA, Brown MD. Molecular mechanisms of metastasis in prostate cancer. Asian J Androl 2009; 11: 57-67
22. Saad F. Bone metastases in advanced prostate cancer. A report. Business briefing. Eur Pharmacother 2005, 2-6. Available from http://www.touchbriefings. com/cdps/cditem.cfm?NID-1134 23.
23. Rigaud J, Tiguert R, Le Normand L, Karam G, Glemain P, Buzelin JM et al. Prognostic value of bone scan in patients with metastatic prostate cancer treated initially with androgen deprivation therapy. J Urol 2002; 168: 1423-1426 (Pubitemid 35034138)
24. Bubendorf L, Schopfer A, Wagner U, Sauter G, Moch H, Willi N et al. Metastatic patterns of prostate cancer: an autopsy study of 1589 patients. Hum Pathol 2000; 31: 578-583 (Pubitemid 30323983)
25. Inoue T, Segawa T, Kamba T, Yoshimura K, Nakamura E, Nishiyama H et al. Prevalence of skeletal complications and their impact on survival of hormone refractory prostate cancer patients in Japan. Urology 2009; 73: 1104-1109
26. Dodwell DJ. Malignant bone resorption: cellular and biochemical mechanisms. Ann Oncol 1992; 3: 257-267
27. Guise TA, Mundy GR. Cancer and bone. Endocr Rev 1998; 19: 18-54 (Pubitemid 29122073)
28. Litwin MS, Hays RD, Fink A, Ganz PA, Leake B, Leach GE et al. Quality-of-life outcomes in men treated for localized prostate cancer. JAMA 1995; 273: 129-135
29. Villavicencio H. Quality of life of patients with advanced and metastatic prostatic carcinoma. Eur Urol 1993; 24(Suppl 2): 118-121 (Pubitemid 23320416)
30. Saad F, Gleason DM, Murray R, Venner P, Tchekmedyian NS, Lacombe L et al. Zoledronic acid is well tolerated for up to 24 months and significantly reduces skeletal complications in patients with advanced prostate cancer metastatic to bone (abstr 1472). Presented at American Urological Association Annual Meeting; 26 April-1 May, 2003; Chicago, Illinois
31. Saad F, Gleason DM, Murray R, Tchekmedyian S, Venner P, Lacombe L et al. Long-term efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic hormone-refractory prostate cancer. J Natl Cancer Inst 2004; 96: 879-882 (Pubitemid 38807610)
32. Cereceda LE, Flechon A, Droz JP. Management of vertebral metastases in prostate cancer: a retrospective analysis in 119 patients. Clin Prostate Cancer 2003; 2: 34-40 (Pubitemid 37012419)
33. Yokomizo A, Koga H, Shinohara N, Miyahara T, Machida N, Tsukino H et al. Skeletal-related events in urological cancer patients with bone metastasis: a multicenter study in Japan. Int J Urol 2010; 17: 332-336
34. Oefelein MG, Ricchiuti V, Conrad W, Resnick MI. Skeletal fractures negatively correlate with overall survival in men with prostate cancer. J Urol 2002; 168: 1005-1007
35. Coleman RE. Metastatic bone disease: clinical features, pathophysiology and treatment strategies. Cancer Treat Rev 2001; 27: 165-176 (Pubitemid 32452017)
36. Kuban DA, el-Mahdi AM, Sigfred SV, Schellhammer PF, Babb TJ. Characteristics of spinal cord compression in adenocarcinoma of prostate. Urology 1986; 28: 364-369
37. Rubin H, Lome LG, Presman D. Neurological manifestation of metastatic prostatic carcinoma. J Urol 1974; 111: 799-802
38. Osborn JL, Getzenberg RH, Trump DL. Spinal cord compression in prostate cancer. J Neurooncol 1995; 23: 135-147
39. Shoskes DA, Perrin RG. The role of surgical management for symptomatic spinal cord compression in patients with metastatic prostate cancer. J Urol 1989; 142: 337-339 (Pubitemid 19197109)
40. Smith EM, Hampel N, Ruff RL, Bodner DR, Resnick MI. Spinal cord compression secondary to prostate carcinoma: treatment and prognosis. J Urol 1993; 149: 330-333 (Pubitemid 23097586)
41. Zelefsky MJ, Scher HI, Krol G, Portenoy RK, Leibel SA, Fuks ZY. Spinal epidural tumor in patients with prostate cancer. Clinical and radiographic predictors of response to radiation therapy. Cancer 1992; 70: 2319-2325
42. Schisterman EF, Cole SR, Platt RW. Overadjustment bias and unnecessary adjustment in epidemiologic studies. Epidemiology 2009; 20: 488-495